Pharma Foods has moved deeper into rare disease drug development by securing exclusive rights to advance adrenomedullin for CADASIL, a hereditary small vessel disorder of the brain with no approved disease-modifying treatment. The Kyoto-based company said the program could help it build a differentiated position in an underserved neurological indication while broadening its biomedical pipeline. The announcement also puts commercial structure around an asset that has already generated academic interest in Japan and been tied to prior work with the National Cerebral and Cardiovascular Center.
Licensing Deal
Under the agreements announced on April 6, Pharma Foods obtained exclusive rights from Himuka AM Pharma and the National Cerebral and Cardiovascular Center to develop and commercialize human adrenomedullin for CADASIL in Japan, South Korea, and Taiwan. The company said the package includes both intellectual property and clinical data, giving it a base to move from research-backed evidence toward commercial development across selected Asian markets. Management framed the program not as an exploratory option but as a potential core pipeline asset with long-term strategic relevance.
Disease Context
CADASIL, short for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, is caused by mutations in the NOTCH3 gene and is associated with premature stroke, progressive cognitive decline, and worsening disability over time. Because there are no approved disease-modifying therapies for the condition, companies and academic centers are working in a field defined more by unmet need than by established commercial precedent. That backdrop helps explain why even regionally scoped licensing deals can attract attention when they are linked to credible clinical groundwork and specialist institutional partners.
Scientific Background
Adrenomedullin is an endogenous peptide known for vasodilatory, anti-inflammatory, and endothelial-protective effects, which has made it a subject of interest in both cardiovascular medicine and disorders involving impaired small-vessel function. A 2024 publication describing the AMCAD study outlined a multicenter, single-arm phase II trial designed to evaluate the safety and efficacy of adrenomedullin in CADASIL, with a planned enrollment of 60 patients and follow-up extending to 180 days. Pharma Foods is drawing on that scientific base, along with prior NCVC-led clinical research, to argue that the program has advanced beyond a purely theoretical concept.
Strategic Significance
The latest deal also fits a broader collaboration pattern between Pharma Foods and NCVC rather than emerging in isolation. In early 2025, Pharma Foods said it had helped establish a dedicated CADASIL drug discovery research department with NCVC, and an NCVC LinkedIn post at the time highlighted adrenomedullin alongside nucleic acid medicines as one of the approaches under study. Seen in that sequence, the new licensing transaction looks like the next formal step in consolidating rights around a program the partners had already been building.
Commercial Outlook
Management said the near-term effect on this fiscal year’s earnings should be limited, but it characterized the asset as a possible medium- to long-term growth driver if development advances as planned. Recent company materials have also said the drug discovery division will continue strengthening R&D investment in antibody and peptide therapeutics, suggesting the CADASIL program fits a broader investment plan rather than a one-off licensing move. For Pharma Foods, the immediate importance of the deal is less about short-term revenue and more about whether it can convert a research collaboration into a clinically advancing regional franchise.
For now, the announcement does not change the treatment landscape for CADASIL, and substantial clinical and regulatory work still lies ahead before adrenomedullin could become a marketed therapy. Even so, the combination of exclusive regional rights, existing academic data, and alignment with a specialist national research center gives Pharma Foods a clearer case for why this program matters. If the company can convert that foundation into credible clinical milestones, the deal could mark an early turning point in the effort to develop a targeted therapy for a disease that has long lacked one.